CareDx and Horizon Discovery Group Enter into a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CareDx and Horizon Discovery Group Enter into a Collaboration for Development of Cell-Free DNA Reference Standards

BRISBANE, Calif. and CAMBRIDGE, United Kingdom, June 3, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA ), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for transplant recipients and Horizon Discovery Group plc (Horizon), an international life science company supplying reagent tools and services that power genomics research and the development of personalized medicines, today announced they have entered into a collaboration to develop cell-free DNA (cfDNA) reference standards. These HDx™ Reference standards, being developed by Horizon Diagnostics, a division of Horizon, will support proficiency testing of CareDx's solid organ transplant injury monitoring diagnostic tests and will be integrated into CLIA laboratory testing.

HDx Reference Standards offer a source of genetically defined, quantitative, sustainable and independent third party reference material, critical to the validation and routine performance monitoring of CareDx's next generation sequencing (NGS) based donor-derived cfDNA (dd-cfDNA) diagnostic assay. The reference standards mimic plasma cfDNA both in size and abundance in transplant setting and are the first commercially available standards of their kind.

Horizon Diagnostics uses its proprietary genome engineering platforms to precisely engineer highly characterized parental cell lines. Horizon Diagnostics then generates mixtures at very precise allelic frequencies, verified by digital PCR, ranging between 0.1% and 50%.

CareDx's cfDNA test is designed to monitor injury to transplanted organs, in particular heart and kidney in transplant recipients to allow clinicians to better manage patient health outcomes. There are approximately 300,000 solid organ transplant patients living in the US. The assay amplifies approximately 250 loci of the human genome to identify transplant donor-recipient pairs with diverse ancestral heritage as well as those with close familial relationships. The CareDx cfDNA assay offers a simpler alternative to assays requiring donor and recipient genotyping to simplify assay implementation.

CareDx's cfDNA test follows recent guidance for next generation sequencing (NGS) outlined by Association of Molecular Pathology (AMP), American College of Medical Genetics (ACMG) and Clinical Laboratory Standards Institute (CLSI). The targeted assay was recognized in the "What's Hot, What's New" session at the American Transplant Congress in Philadelphia on May 6, 2015.

Dr. Paul Morrill, President, Products Business, Horizon, said: "This new collaboration with CareDx demonstrates the importance of well validated controls when developing clinical assays, especially as technologies such as NGS become more widely adopted for diagnostic use. Horizon is committed and motivated to be working with CareDx on the development of cell-free DNA reference standards within the solid organ transplant field, taking our reference standard technology into a new area beyond Oncology."

Dr. John J. Sninsky, CSO of CareDx, commented: "I have been working with Horizon's scientists for more than five years, and am continually impressed by their understanding of diagnostic requirements. At CareDx, it is our goal to accelerate patient access to clinical data using next generation sequencing technology. This collaboration with Horizon has the potential to advance us to this goal, and demonstrates CareDx's continued quality and regulatory leadership."

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. The Company is currently investigating a research use only donor-derived cell-free DNA-based test for heart transplant recipients. For more information, please visit: www.CareDx.com .

About Horizon Discovery Group plc www.horizondiscovery.com/

Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base of over 1,000 organizations across nearly 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon's core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers over 16,000 products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These 'patients-in-a-test-tube' are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides rAAV, ZFN and CRISPR gene editing tools, custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, contract research and custom screening services and custom shRNA development services and off-the-shelf validated shRNA (through Horizon's partner Sirion).

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD", for further information please visit: www.horizondiscovery.com .

About Horizon Diagnostics www.horizondx.com

Horizon Diagnostics, a division of Horizon Discovery Group plc, is a leading provider of genetically defined, human genomic reference standards, including FFPE cell line sections and purified genomic DNA. HDx™ Reference Standards offer a sustainable source of reference material to laboratories, proficiency schemes and manufacturers, providing an unprecedented level of control.

Variability in DNA extraction from tumor biopsies and a lack of standardization are currently major sources of error in molecular laboratories. The availability of genetically defined reference materials provides an industry standard for development and quality control of molecular assays, directly improving their accuracy.

Horizon Diagnostics' suite of HDx Reference Standards includes standards for the increasing number of 'rare' mutations being targeted for cancer therapeutics, which by definition are hard to find in clinical samples.

Drawing upon Horizon Discovery's proprietary genome editing platform, Horizon Diagnostics reconstitutes clinically relevant cancer genes in human cell lines, exactly as they occur in patient tumors. Horizon Diagnostics is able to define virtually every characteristic of its reference standards, from the molecular constitution of the genome to the diameter, width and DNA output associated with each product batch. These standards have been made available in a variety of formats including genomic DNA (gDNA) aliquots, Formalin-Fixed Paraffin-Embedded (FFPE) slices, fluorescent in-situ hybridization (FISH) material and immunohistochemistry (IHC) assays.

Forward Looking Statements

This press release contains forward-looking statements including, but not limited to statements regarding the Company's expectations regarding future potential, development and commercial activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including CareDx's limited operating history and experience with developing new markets; risk relating to new partnerships and commercialization of those relationships, as well as other risks stated in CareDx's filings with the SEC located at www.sec.gov . CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contacts For Horizon Discovery Katie Odgaard Zyme Communications T: +44 (0)7787 502 947 E: For CareDx Jamie Autorino Marketing Manager T: +1 415-287-2313 E: For Investors Westwicke Partners, LLC Leigh J. Salvo Principal T: +1 415-513-1281 E:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 223

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 438

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 284

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 430

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 316

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 226

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 358

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

How Recent Tax Changes Favor Robinhood Markets in Gambling

Updated Category News Views 1112

How Recent Tax Changes Favor Robinhood Markets in Gambling A small detail in recent legislation has the potential to transform the landscape of professional sports betting across the U.S. The One Big Beautiful Bill (OBBB) Act introduces a shift in tax policy that impacts how professional gamblers are taxed compared to stock and options traders. Under this new framework,...

Continue Reading
Bloomberg Launches Generative AI for Enhanced Document Analysis

Updated Category News Views 851

Revolutionizing Financial Research with AI Innovations Bloomberg has taken a significant step forward in financial analysis with the introduction of AI-Powered Document Insights. This innovative solution enables research analysts and corporate decision-makers to ask complex questions and receive insightful answers from company documents using everyday conversational...

Continue Reading
Sidus Space Sees Remarkable Stock Growth After Key Announcements

Updated Category News Views 153

Why Is Sidus Space Stock Surging? Sidus Space (NASDAQ: SIDU) has caught the attention of investors with its impressive stock surge, recently climbing to $2.87, a rise of $0.67 or about 30.45%. This remarkable movement in share price follows notable announcements by the company. Significant Financing Through Public Offering On December 24, Sidus Space revealed that it had...

Continue Reading
Kuraray's Strategic Move: Acquiring Nelumbo for Growth

Updated Category News Views 348

Kuraray Expands Its Horizons with Nelumbo Acquisition Kuraray Co., Ltd. has embarked on an exciting journey by acquiring Nelumbo Inc., a forward-thinking company known for its unique materials technology for surface modification. Although the financial details of this acquisition remain confidential, the strategic implications are substantial. Discovering Nelumbo’s...

Continue Reading
Appfire Appoints Matt Dircks as New CEO for Future Growth

Updated Category News Views 682

Exciting Leadership Change at Appfire In a significant move for Appfire, the company has appointed Matt Dircks as its new CEO, succeeding founding leader Randall Ward. This change represents a pivotal moment for Appfire as it looks to elevate its growth trajectory, fueled by a solid vision and strategic direction. Randall Ward's Legacy and Transition Randall Ward, who has...

Continue Reading